Clinical Trial: Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Multi-center Study Evaluating OraVescent Fentanyl Citrate for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients

Brief Summary: The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl when used long-term to relieve breakthrough pain in opioid tolerant cancer patients.

Detailed Summary:
Sponsor: Cephalon

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Teva Pharmaceutical Industries

Dates:
Date Received: March 11, 2005
Date Started: January 2005
Date Completion:
Last Updated: May 8, 2014
Last Verified: May 2014